Cytochrome P450 (Other isoforms) (CYP)

Cytochrome P450 (CYP) enzymes represent a vast superfamily of heme-thiolate proteins essential for the metabolism of drugs, toxins, and endogenous substances such as steroids and lipids (Guengerich, 2008, Chemical Research in Toxicology). While major isoforms like CYP3A4 and CYP2D6 are responsible for the majority of clinical drug metabolism, other isoforms including CYP1A2, CYP2C8, CYP2E1, and members of the CYP4 family contribute significantly to the biotransformation of specific therapeutic classes and environmental chemicals (Zanger & Schwab, 2013, Pharmacology & Therapeutics). These enzymes primarily catalyze monooxygenation reactions in the liver's endoplasmic reticulum, facilitating the clearance of lipophilic compounds from the body (Nebert & Dalton, 2006, Nature Reviews Drug Discovery). In the context of pharmacology, these isoforms are critical targets for assessing drug-drug interactions, as many medications act as inhibitors or inducers of these enzymes, potentially leading to toxic accumulations or sub-therapeutic levels of co-administered drugs (Lynch & Price, 2007, American Family Physician). Furthermore, genetic variations in these other CYP isoforms can lead to distinct phenotypes, such as poor or ultra-rapid metabolizers, which necessitate personalized dosing strategies to ensure patient safety (Ingelman-Sundberg, 2004, Trends in Pharmacological Sciences). Monitoring the activity of these enzymes is a standard part of ADME profiling in pharmaceutical development to predict potential toxicities and optimize drug design.

Other names

Cytochrome P450 superfamilyCYP450Microsomal monooxygenaseHeme-thiolate enzymes

Enzymatic oxidation of substrates; competitive and non-competitive inhibition; induction of enzyme expression via nuclear receptor activation (e.g., PXR, CAR).